Type 2 Diabetes Therapy
Research on type 2 diabetes therapy detailed by scientists at Central South University, Institute of Clinical Pharmacology
Published in Medical Device Business Week, August 26th, 2009
New investigation results, 'Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes,' are detailed in a study published in British Journal of Clinical Pharmacology. "The aim of this study was to explore the impact of UCP2 and ADRB3 genetic polymorphisms on the therapeutic efficacy of rosiglitazone in Chinese Type 2 diabetes (T2DM) patients. A total of 199 T2DM patients and 155 healthy volunteers were enrolled to identify UCP2 -866 G/A genotypes, and 273 T2DM patients and 166 controls were genotyped for Trp64Arg of ADRB3 by polymerase chain reaction-restriction fragment length polymorphism assay," scientists writing in the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
More Articles from Medical Device Business Week
- Angiotech Pharmaceuticals, Inc.
Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent - Artificial Organs
Hypertronics HyperGrip(R) and D Series Connectors Selected for SynCardia's Total Artificial Heart - Avnet Electronics Marketing
Avnet Electronics Marketing and Projects Unlimited Audio Ink Americas Distribution Agreement - Biotechnology Business
Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products - Blood Pressure
Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan - Cancer
Report summarizes cancer study findings from Memorial Sloan Kettering Cancer Center, Department of Surgery - More from this issue of Medical Device Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
